Lv1
40 积分 2023-12-18 加入
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study
6小时前
待确认
A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL‐321
12小时前
已完结
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome
3个月前
已完结
Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis
5个月前
已完结
Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
5个月前
已关闭
Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma
6个月前
已完结
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
6个月前
已完结
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration
6个月前
已完结
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
6个月前
已完结
How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
6个月前
已完结
皖公网安备34019202002308
